Latest Health News

Verbrec Limited has reported a remarkable turnaround in its half-year results, posting a $9 million net profit and announcing its first interim dividend in the current period. Strategic acquisitions and a sharp rise in net tangible assets underpin this strong performance.

ECS Botanics has reported a return to profitability and positive cash flow in the first half of FY26, driven by a strategic shift to branded products and major infrastructure expansion.

Future Generation Global Limited reported a 50% drop in net profit for 2025 but maintained strong investment portfolio growth and declared a special fully franked dividend, while continuing its significant social impact contributions.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

6K Additive, a US-based metal powder innovator, reports a 3.85% revenue dip to US$17.7 million and narrows net loss to US$17.9 million in its first ASX-listed year. The company plans a fivefold capacity expansion backed by significant government grants and a US$27.4 million loan.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

Jupiter Mines Limited reported a 15.7% rise in profit after tax for HY2026, driven by its stake in the Tshipi manganese mine and a key joint venture deal with Exxaro Resources. The company navigates production challenges and market shifts while preparing for a dividend decision.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Metals X Limited reported a robust 2025 financial year with revenue up 30% to $285 million, driven by higher tin prices despite a slight dip in production. The company is advancing its key growth project, Rentails, targeting a final investment decision in late 2026.

Dataworks Group Limited reported a significant reduction in its half-year loss alongside a major contract extension in Ontario, marking a pivotal shift to positive cash flow.

Frontier Energy Limited has reported a sharp 71% increase in net loss for the year ended 31 December 2025, with no dividends declared and a slight dip in net tangible assets per share.